In the first report on the testing of IFN-α as an adjuvant in the vaccination of cancer patients, 7 stage IV melanoma patients were injected with MART-1 and gp-100 peptides, and IFN-α was administered in close spatial and temporal proximity to the peptide vaccine. The gene discussed is PMEL; the disease is melanoma.